Ocular Therapeutix (OCUL) Stock Price, News & Analysis

Company Overview

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation following ophthalmic surgery. Ocular Therapeutix also markets ReSure® Sealant, a synthetic polyethylene glycol-based hydrogel approved to seal corneal incisions and reduce postoperative fluid egress. These products exemplify the company’s strategy of combining novel delivery systems with established drug compounds to enhance safety and efficacy.

In addition to its marketed therapies, Ocular Therapeutix maintains a pipeline of investigational candidates targeting conditions such as glaucoma and dry eye disease. Key programs include OTX-TKI, a tyrosine kinase inhibitor insert under development for glaucoma, and OTX-DED, an insert incorporating low-dose dexamethasone for chronic dry eye. The company leverages partnerships and licensing agreements to expand its technology platform and advance clinical programs.

Led by Chief Executive Officer Antony Mattessich, Ocular Therapeutix operates manufacturing and research facilities in the United States and collaborates with contractors and distributors to support commercialization. The company’s management team combines expertise in ophthalmology, drug delivery, and regulatory affairs to guide product approvals and market access strategies within the U.S. and select international markets.

Key Stats

• Today's Range: $9.55 to $9.98
• 50-Day Range: $7.40 to $11.04
• 52-Week Range: $6.23 to $16.44
• Volume: 3.79 million shs
• Average Volume: 5.41 million shs
• Market Capitalization: $2.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.78
• Consensus Rating: Moderate Buy

Ocular Therapeutix Stock Analysis - MarketRank™

Ocular Therapeutix scored higher than 65% of companies evaluated by MarketBeat, and ranked 257th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ocular Therapeutix has a consensus price target of $23.78, representing about 144.9% upside from its current price of $9.71.

Amount of Analyst Coverage

Ocular Therapeutix has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.29) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocular Therapeutix is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocular Therapeutix is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ocular Therapeutix has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.53% of the float of Ocular Therapeutix has been sold short.

Short Interest Ratio / Days to Cover

Ocular Therapeutix has a short interest ratio ("days to cover") of 6.99.

Change versus previous month

Short interest in Ocular Therapeutix has recently decreased by 2.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocular Therapeutix does not currently pay a dividend.

Dividend Growth

Ocular Therapeutix does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.06

News Sentiment

Ocular Therapeutix has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Ocular Therapeutix this week, compared to 5 articles on an average week.

Search Interest

Only 24 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

6 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ocular Therapeutix insiders have sold 258.38% more of their company's stock than they have bought. Specifically, they have bought $461,354.00 in company stock and sold $1,653,407.00 in company stock.

Percentage Held by Insiders

2.30% of the stock of Ocular Therapeutix is held by insiders.

Percentage Held by Institutions

59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OCUL Stock Analysis - Frequently Asked Questions

How have OCUL shares performed this year?

Ocular Therapeutix's stock was trading at $12.14 at the beginning of 2026. Since then, OCUL stock has decreased by 20.0% and is now trading at $9.71.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.08. The business's revenue for the quarter was up .8% compared to the same quarter last year.
Read the conference call transcript.

When did Ocular Therapeutix IPO?

Ocular Therapeutix (OCUL) raised $75 million in an initial public offering (IPO) on Friday, July 25th 2014. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Who are Ocular Therapeutix's major shareholders?

Top institutional shareholders of Ocular Therapeutix include Summer Road LLC (5.46%), Deltec Asset Management LLC (1.08%), Candriam S.C.A. (0.44%) and Peregrine Capital Management LLC (0.33%). Insiders that own company stock include Summer Road Llc, Pravin Dugel, Antony C Mattessich, Donald Notman, Sanjay Nayak, Jeffrey S Heier, Nadia Waheed, Peter Kaiser, Richard L Md Lindstrom, Philip C Strassburger, Rabia Gurses Ozden and Todd Anderman.
View institutional ownership trends.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Stifel 2026 Virtual Ophthalmology Forum: 5/26/2026
• Investor Day 2026: 6/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCUL
• CIK: 1393434
• Web: www.ocutx.com
• Phone: (781) 357-4000
• Fax: 781-357-4001
• Employees: 230
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Ocular Therapeutix: $23.78
• High Price Target: $31.00
• Low Price Target: $18.00
• Potential Upside/Downside: +144.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$265.94 million
• Net Margins: -511.90%
• Pretax Margin: -511.90%
• Return on Equity: -70.68%
• Return on Assets: -50.53%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 15.39
• Quick Ratio: 15.32

Sales & Book Value

• Annual Sales: $51.95 million
• Price / Sales: 40.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 3.16

Miscellaneous

• Outstanding Shares: 218,910,000
• Free Float: 212,685,000
• Market Cap: $2.13 billion
• Optionable: Optionable
• Beta: 0.93